PTPN1 and metabolic syndrome: Fumosorinone (10) acts as a classic non-competitive inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 14.04 μM, which suggests that it is a potential medicine for the treatment of type II diabetes and other associated metabolic syndromes.